Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council -…
Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council - Futuximab, American Medical Association. It acts as an immunomodulator and also binds to HER1.
This drug was developed by Symphogen.
References
Gebaseerd op: Wikipedia — Futuximab · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.